Advances in Pharmacology publishes a review article authored by APIM's CSO and NTNU Professor Marit Otterlei focusing on stress-related roles of proliferating cell nuclear antigen (PCNA) and how targeting these PCNA roles can be exploited in cancer therapy. A copy of the corresponding article is available here.
Clinical Research News features an article on APIM's development program highlighting key attributes of the underlying mechanism of action of ATX-101 and results from the first-in-human clinical study that has been concluded with the compound. Additional insights and information on the on-going clinical studies in ovarian cancer and sarcoma are presented by APIM's CMO, Jens-Peter Marschner and APIM's CSO and NTNU Professor Marit Otterlei. A copy of the corresponding article is available here.
Norwegian SciTech News features an article on APIM's drug candidate ATX-101 highlighting the development path pursued since its discovery by APIM's CSO and NTNU Professor Marit Otterlei, up until its current status in clinical trials. A copy of the article is available here.
NRK Dagsrevyen hosts APIM's CSO and NTNU Professor Marit Otterlei in today's news presenting the latest updates on ATX-101's development and future potential. To see the broadcast, please visit this link (starts after 22.42 minutes in the broadcast).
Oncogene publishes a study authored by NTNU Professor and APIM Therapeutics's CSO Marit Otterlei and co-workers. In the article entitled “PCNA regulates primary metabolism by scaffolding metabolic enzymes“, it was shown for the first time that Proliferating Nuclear Cell Antigen (PCNA) is a cytosolic scaffold protein important for regulating primary metabolism and thereby cellular signaling. This data support the phase 1 clinical results obtained with ATX-101, published back to back in the same issue of Oncogene. For more information on this article, please visit this link.
APIM Therapeutics announced today that the phase 1 data of APIM's lead compound ATX-101 have been published in Oncogene. The data confirm that PCNA is an interesting target for the treatment of cancer. ATX-101 can be administered safely and shows clinical activity. Phase 2 studies are ongoing to demonstrate proof of concept. For more information, please follow this link.
APIM Therapeutics annouced today that since the proposed merger transaction with Nordic Nanovector ASA, a listed Norwegian biotechnology company (OSE: NANOV), did not obtain sufficient majority of votes at the Extraordinary General Meeting of the shareholders of Nordic Nanovector held on December 1st, 2022, the planned all-stock transaction between the companies was thereby cancelled. APIM Therapeutics will continue advancing its lead candidate ATX-101 in clinical trials, expecting to meet significant milestones in the period of 2023 & 2024.
The shareholders of APIM Therapeutics and Nordic Nanovector ASA, a listed Norwegian biotechnology company (OSE: NANOV), have announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing a portfolio of clinical and preclinical oncology programs including multiple clinical studies for its lead candidate ATX-101. For more information about the merger agreement, please read the corresponding press release.
APIM Therapeutics announced today that Columbia University (CU) will be presenting a clinical-trial-in-progress poster at the ASCO annual meeting showing the design of their phase 2 study with our lead compound ATX-101. APIM supports this investigator sponsored clinical trial in patients suffering from lipo- and leiomyosarcoma. This is the second ongoing clinical phase 2 study with ATX-101.The poster presentation can be visited in Hall A starting at 8:00am (abstract #: TPS11587; poster BD #: 488b, see also here).
APIM Therapeutics announced today the publication of research data of ATX-101 in glioblastoma preclinical models in the peer reviewed journal Cancers. The study, conducted in a panel of human glioblastoma and patient-derived glioma-initiating cells, showed that ATX-101 has anticancer activity as a single agent in vitro and in vivo. Furthermore, it potentiated the effect of Radiotherapy in both subcutaneous and intracranial xenograft tumor models. For a copy of the corresponding press release, please follow this link.
APIM Therapeutics announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia University Irving Medical Center. The clinical study will investigate ATX-101 as single agent therapy for patients with leiomyosarcoma and liposarcoma who have received at least one prior treatment. For a copy of the corresponding press release, please follow this link.
APIM Therapeutics announced today that the first patient has been treated with ATX-101 in the company's phase I/II ovarian cancer study. The clinical study investigates ATX-101 in combination with platinum-based chemotherapy and comprises two parts: Part 1 is a safety part with dose limiting toxicity as primary endpoint; Part 2 is an efficacy part with progression free survival as primary endpoint. For a copy of the corresponding press release, please follow this link.
APIM Therapeutics has presented a poster summarizing results from its on-going first-in-human clinical study with ATX-101 in advanced cancer patients during the Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting. A copy of the presented poster can be downloaded here.
APIM Therapeutics's abstract summarizing results from our first-in-human clinical study with ATX-101 in advanced cancer patients has now been posted on the website of the American Society of Clinical Oncology (ASCO) Annual Meeting (please follow this link). The corresponding poster will be presented at the Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology Session on June 4, starting at 3:00 pm.
APIM Therapeutics announced today completion of a private placement round by existing and new investors. With the proceeds from the private placement, the company will initiate a proof-of-concept combination study in recurrent ovarian cancer and support a Phase-2 investigator-initiated study in sarcoma. For a copy of the corresponding press release, please follow this link.
APIM Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial will be conducted in Australia, South Korea and Taiwan. A copy of the corresponding press release is provided here.
Phase I clinical data of APIM’s lead compound ATX-101 will be presented at the 2021 ASCO Annual Meeting. The poster with the title: “A first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA), shows a favorable safety profile and disease stabilization in late stage, heavily pre-treated, solid tumor patients” (abstract 3067), will be presented by Dr. Charlotte Lemech at the poster session “Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology” on June 4 starting at 3:00 pm.
APIM Therapeutics was nominated as a top venture capital company in Norway by the Welp Magazine (#WelpMagazine). Please visit this link for more information.
Nucleic Acids Research publishes a study authored by NTNU Professor and APIM Therapeutics's CSO Marit Otterlei and co-workers. The study shows that peptides containing the PCNA interacting motif APIM bind to the β-clamp and inhibit bacterial growth and mutagenesis. These results suggest that APIM-peptides could have clinical applications in combination with other antibiotics and as single agents. A copy of the publication is available here.
Oncotarget publishes a study authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper focuses on non-canonical cytosolic roles of PCNA targeted by ATX-101, a cell-penetrating peptide containing the PCNA-interacting motif APIM. The results showed that ATX-101 increased the anti-cancer activity of EGFR/HER2/VEGFR inhibitors in vitro and in vivo. These results suggest that targeting the non-canonical roles of PCNA in cellular signaling with ATX-101 has the potential to improve the efficacy of targeted therapies. A copy of the publication is available here.